Skip to main content
main-content
Erschienen in: Herz 1/2018

15.01.2018 | Koronare Herzerkrankung | CME

Prävention von Herz-Kreislauf-Erkrankungen

verfasst von: Dr. med. J. H. Prochaska, N. Arnold, C. Jünger, T. Münzel, Univ.-Prof. Dr. med. P. S. Wild

Erschienen in: Herz | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Auftreten von kardiovaskulären Erkrankungen kann durch Früherkennung und gezielte Behandlung von Risikofaktoren und der subklinischen Erkrankung reduziert werden. Die Maßnahmen auf dem Gebiet der Primärprävention umfassen vielfältige Möglichkeiten zur erfolgreichen Intervention. Neben einer medikamentösen Therapie sind v. a. lebensstilverändernde Maßnahmen wie körperliche Aktivität, Normalisierung des Körpergewichts, konsequente Nikotinabstinenz sowie die Berücksichtigung psychosozialer Aspekte zentrale Kernbestandteile von Präventionsprogrammen. Versorgungsmedizinische Untersuchungen zeigen, dass Risikofaktoren oft unerkannt bleiben bzw. das volle Potenzial des Managements von Risikofaktoren noch nicht optimal ausgeschöpft wird. Hierbei kommt v. a. der Motivation und Therapieadhärenz der Patienten eine entscheidende Rolle zu.
Literatur
1.
Zurück zum Zitat GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet 390(10100):1211–1259 CrossRef GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet 390(10100):1211–1259 CrossRef
2.
Zurück zum Zitat Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105(9):1135–1143 CrossRefPubMed Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105(9):1135–1143 CrossRefPubMed
3.
Zurück zum Zitat Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937–952 CrossRefPubMed Yusuf S, Hawken S, Ounpuu S et al (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438):937–952 CrossRefPubMed
4.
Zurück zum Zitat Khot UN, Khot MB, Bajzer CT et al (2003) Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290(7):898–904 CrossRefPubMed Khot UN, Khot MB, Bajzer CT et al (2003) Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290(7):898–904 CrossRefPubMed
5.
Zurück zum Zitat Criqui MH, Barrett-Connor E, Holdbrook MJ et al (1980) Clustering of cardiovascular disease risk factors. Prev Med 9(4):525–533 CrossRefPubMed Criqui MH, Barrett-Connor E, Holdbrook MJ et al (1980) Clustering of cardiovascular disease risk factors. Prev Med 9(4):525–533 CrossRefPubMed
6.
Zurück zum Zitat Piepoli MF, Hoes AW, Agewall S et al (2016) 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J 37(29):2315–2381 CrossRefPubMedPubMedCentral Piepoli MF, Hoes AW, Agewall S et al (2016) 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J 37(29):2315–2381 CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mortensen MB, Nordestgaard BG, Afzal S et al (2017) ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen general population study. Eur Heart J 38(8):586–594 PubMed Mortensen MB, Nordestgaard BG, Afzal S et al (2017) ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen general population study. Eur Heart J 38(8):586–594 PubMed
8.
Zurück zum Zitat Ray KK, Kastelein JJ, Boekholdt SM et al (2011) The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 35(15):960–968 CrossRef Ray KK, Kastelein JJ, Boekholdt SM et al (2011) The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 35(15):960–968 CrossRef
9.
Zurück zum Zitat Lewington S, Clarke R, Qizilbash N et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349):1903–1913 CrossRefPubMed Lewington S, Clarke R, Qizilbash N et al (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349):1903–1913 CrossRefPubMed
10.
Zurück zum Zitat Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338:b1665 CrossRefPubMedPubMedCentral Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338:b1665 CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Vasan RS, Beiser A, Seshadri S et al (2002) Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham heart study. JAMA 287(8):1003–1010 CrossRefPubMed Vasan RS, Beiser A, Seshadri S et al (2002) Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham heart study. JAMA 287(8):1003–1010 CrossRefPubMed
12.
Zurück zum Zitat Vasan RS, Larson MG, Leip EP et al (2001) Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345(18):1291–1297 CrossRefPubMed Vasan RS, Larson MG, Leip EP et al (2001) Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345(18):1291–1297 CrossRefPubMed
13.
Zurück zum Zitat Schwartz JE, Burg MM, Shimbo D et al (2016) Clinic blood pressure underestimates ambulatory blood pressure in an untreated employer-based US population: results from the masked hypertension study. Circulation 134(23):1794–1807 CrossRefPubMedPubMedCentral Schwartz JE, Burg MM, Shimbo D et al (2016) Clinic blood pressure underestimates ambulatory blood pressure in an untreated employer-based US population: results from the masked hypertension study. Circulation 134(23):1794–1807 CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Pierdomenico SD, Cuccurullo F (2011) Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens 24(1):52–58 CrossRefPubMed Pierdomenico SD, Cuccurullo F (2011) Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens 24(1):52–58 CrossRefPubMed
15.
Zurück zum Zitat Wright JT Jr., Williamson JD, Whelton PK et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103–2116 CrossRefPubMed Wright JT Jr., Williamson JD, Whelton PK et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103–2116 CrossRefPubMed
16.
Zurück zum Zitat Ettehad D, Emdin CA, Kiran A et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387(10022):957–967 CrossRefPubMed Ettehad D, Emdin CA, Kiran A et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387(10022):957–967 CrossRefPubMed
17.
Zurück zum Zitat Egan BM, Zhao Y, Axon RN (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 303(20):2043–2050 CrossRefPubMed Egan BM, Zhao Y, Axon RN (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 303(20):2043–2050 CrossRefPubMed
18.
Zurück zum Zitat Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219 CrossRefPubMed Mancia G, Fagard R, Narkiewicz K et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159–2219 CrossRefPubMed
19.
Zurück zum Zitat Thom S, Poulter N, Field J et al (2013) Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310(9):918–929 CrossRefPubMed Thom S, Poulter N, Field J et al (2013) Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 310(9):918–929 CrossRefPubMed
20.
Zurück zum Zitat Appel LJ, Brands MW, Daniels SR et al (2006) Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 47(2):296–308 CrossRefPubMed Appel LJ, Brands MW, Daniels SR et al (2006) Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 47(2):296–308 CrossRefPubMed
21.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR et al (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19):2560–2572 CrossRefPubMed Chobanian AV, Bakris GL, Black HR et al (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289(19):2560–2572 CrossRefPubMed
22.
Zurück zum Zitat Wilson PW, Kannel WB, Anderson KM (1985) Lipids, glucose intolerance and vascular disease: the Framingham study. Monogr Atheroscler 13:1–11 PubMed Wilson PW, Kannel WB, Anderson KM (1985) Lipids, glucose intolerance and vascular disease: the Framingham study. Monogr Atheroscler 13:1–11 PubMed
23.
Zurück zum Zitat Grossmann V, Schmitt VH, Zeller T et al (2015) Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care 38(7):1356–1364 CrossRefPubMed Grossmann V, Schmitt VH, Zeller T et al (2015) Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care 38(7):1356–1364 CrossRefPubMed
24.
Zurück zum Zitat Ryden L, Grant PJ, Anker SD et al (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34(39):3035–3087 CrossRefPubMed Ryden L, Grant PJ, Anker SD et al (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34(39):3035–3087 CrossRefPubMed
25.
Zurück zum Zitat Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393–403 CrossRefPubMed Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393–403 CrossRefPubMed
26.
Zurück zum Zitat Howard BV, Best LG, Galloway JM et al (2006) Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 29(2):391–397 CrossRefPubMed Howard BV, Best LG, Galloway JM et al (2006) Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care 29(2):391–397 CrossRefPubMed
27.
Zurück zum Zitat Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128 CrossRefPubMed Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128 CrossRefPubMed
28.
29.
Zurück zum Zitat Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253:281–344 CrossRefPubMed Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253:281–344 CrossRefPubMed
30.
Zurück zum Zitat Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278 CrossRefPubMed Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278 CrossRefPubMed
31.
Zurück zum Zitat Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999–3058 CrossRefPubMed Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999–3058 CrossRefPubMed
32.
Zurück zum Zitat Berrington de Gonzalez A, Hartge P, Cerhan JR et al (2010) Body-mass index and mortality among 1.46 million white adults. N Engl J Med 363(23):2211–2219 CrossRefPubMed Berrington de Gonzalez A, Hartge P, Cerhan JR et al (2010) Body-mass index and mortality among 1.46 million white adults. N Engl J Med 363(23):2211–2219 CrossRefPubMed
33.
Zurück zum Zitat Robinson JG, Farnier M, Krempf M et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1489–1499 CrossRefPubMed Robinson JG, Farnier M, Krempf M et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1489–1499 CrossRefPubMed
34.
Zurück zum Zitat Sabatine MS, Giugliano RP, Keech AC et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713–1722 CrossRefPubMed Sabatine MS, Giugliano RP, Keech AC et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713–1722 CrossRefPubMed
35.
Zurück zum Zitat Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384(9943):626–635 CrossRefPubMed Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384(9943):626–635 CrossRefPubMed
36.
Zurück zum Zitat Waldeyer C, Makarova N, Zeller T et al (2017) Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J 38(32):2490–2498 CrossRefPubMed Waldeyer C, Makarova N, Zeller T et al (2017) Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J 38(32):2490–2498 CrossRefPubMed
37.
Zurück zum Zitat Voight BF, Peloso GM, Orho-Melander M et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380(9841):572–580 CrossRefPubMedPubMedCentral Voight BF, Peloso GM, Orho-Melander M et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380(9841):572–580 CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Nordestgaard BG, Chapman MJ, Ray K et al (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31(23):2844–2853 CrossRefPubMedPubMedCentral Nordestgaard BG, Chapman MJ, Ray K et al (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31(23):2844–2853 CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Prescott E, Hippe M, Schnohr P et al (1998) Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 316(7137):1043–1047 CrossRefPubMedPubMedCentral Prescott E, Hippe M, Schnohr P et al (1998) Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 316(7137):1043–1047 CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Ott A, Slooter AJ, Hofman A et al (1998) Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam study. Lancet 351(9119):1840–1843 CrossRefPubMed Ott A, Slooter AJ, Hofman A et al (1998) Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: the Rotterdam study. Lancet 351(9119):1840–1843 CrossRefPubMed
41.
Zurück zum Zitat Barone-Adesi F, Vizzini L, Merletti F et al (2006) Short-term effects of Italian smoking regulation on rates of hospital admission for acute myocardial infarction. Eur Heart J 27(20):2468–2472 CrossRefPubMed Barone-Adesi F, Vizzini L, Merletti F et al (2006) Short-term effects of Italian smoking regulation on rates of hospital admission for acute myocardial infarction. Eur Heart J 27(20):2468–2472 CrossRefPubMed
42.
Zurück zum Zitat Lampert T, von der Lippe E, Muters S (2013) Prevalence of smoking in the adult population of Germany: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56(5–6):802–808 CrossRefPubMed Lampert T, von der Lippe E, Muters S (2013) Prevalence of smoking in the adult population of Germany: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56(5–6):802–808 CrossRefPubMed
43.
Zurück zum Zitat He J, Vupputuri S, Allen K et al (1999) Passive smoking and the risk of coronary heart disease – a meta-analysis of epidemiologic studies. N Engl J Med 340(12):920–926 CrossRefPubMed He J, Vupputuri S, Allen K et al (1999) Passive smoking and the risk of coronary heart disease – a meta-analysis of epidemiologic studies. N Engl J Med 340(12):920–926 CrossRefPubMed
45.
Zurück zum Zitat Benowitz NL, Fraiman JB (2017) Cardiovascular effects of electronic cigarettes. Nat Rev Cardiol 14(8):447–456 CrossRefPubMed Benowitz NL, Fraiman JB (2017) Cardiovascular effects of electronic cigarettes. Nat Rev Cardiol 14(8):447–456 CrossRefPubMed
46.
Zurück zum Zitat Mons U, Muezzinler A, Gellert C et al (2015) Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ 350:h1551 CrossRefPubMedPubMedCentral Mons U, Muezzinler A, Gellert C et al (2015) Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ 350:h1551 CrossRefPubMedPubMedCentral
47.
48.
Zurück zum Zitat Finucane MM, Stevens GA, Cowan MJ et al (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377(9765):557–567 CrossRefPubMedPubMedCentral Finucane MM, Stevens GA, Cowan MJ et al (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377(9765):557–567 CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Despres JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444(7121):881–887 CrossRefPubMed Despres JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444(7121):881–887 CrossRefPubMed
51.
Zurück zum Zitat Tang WH, Hazen SL (2017) The gut microbiome and its role in cardiovascular diseases. Circulation 135(11):1008–1010 CrossRefPubMed Tang WH, Hazen SL (2017) The gut microbiome and its role in cardiovascular diseases. Circulation 135(11):1008–1010 CrossRefPubMed
52.
Zurück zum Zitat Kim SH, Despres JP, Koh KK (2016) Obesity and cardiovascular disease: friend or foe? Eur Heart J 37(48):3560–3568 CrossRefPubMed Kim SH, Despres JP, Koh KK (2016) Obesity and cardiovascular disease: friend or foe? Eur Heart J 37(48):3560–3568 CrossRefPubMed
53.
Zurück zum Zitat Sattelmair J, Pertman J, Ding EL et al (2011) Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 124(7):789–795 CrossRefPubMedPubMedCentral Sattelmair J, Pertman J, Ding EL et al (2011) Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 124(7):789–795 CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Bangalore S, Fayyad R, Laskey R et al (2017) Body-weight fluctuations and outcomes in coronary disease. N Engl J Med 376(14):1332–1340 CrossRefPubMed Bangalore S, Fayyad R, Laskey R et al (2017) Body-weight fluctuations and outcomes in coronary disease. N Engl J Med 376(14):1332–1340 CrossRefPubMed
55.
Zurück zum Zitat O’Leary DH, Polak JF, Kronmal RA et al (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. N Engl J Med 340(1):14–22 CrossRefPubMed O’Leary DH, Polak JF, Kronmal RA et al (1999) Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. N Engl J Med 340(1):14–22 CrossRefPubMed
56.
Zurück zum Zitat Chambless LE, Heiss G, Folsom AR et al (1997) Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 146(6):483–494 CrossRefPubMed Chambless LE, Heiss G, Folsom AR et al (1997) Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987–1993. Am J Epidemiol 146(6):483–494 CrossRefPubMed
57.
Zurück zum Zitat Sinning C, Wild PS, Echevarria FM et al (2011) Sex differences in early carotid atherosclerosis (from the community-based Gutenberg-Heart Study). Am J Cardiol 107(12):1841–1847 CrossRefPubMed Sinning C, Wild PS, Echevarria FM et al (2011) Sex differences in early carotid atherosclerosis (from the community-based Gutenberg-Heart Study). Am J Cardiol 107(12):1841–1847 CrossRefPubMed
58.
Zurück zum Zitat Den Ruijter HM, Peters SA, Anderson TJ et al (2012) Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 308(8):796–803 CrossRef Den Ruijter HM, Peters SA, Anderson TJ et al (2012) Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 308(8):796–803 CrossRef
59.
Zurück zum Zitat Townsend RR, Wilkinson IB, Schiffrin EL et al (2015) Recommendations for improving and standardizing vascular research on arterial stiffness: a scientific statement from the American Heart Association. Hypertension 66(3):698–722 CrossRefPubMedPubMedCentral Townsend RR, Wilkinson IB, Schiffrin EL et al (2015) Recommendations for improving and standardizing vascular research on arterial stiffness: a scientific statement from the American Heart Association. Hypertension 66(3):698–722 CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Ben-Shlomo Y, Spears M, Boustred C et al (2014) Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 63(7):636–646 CrossRefPubMed Ben-Shlomo Y, Spears M, Boustred C et al (2014) Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 63(7):636–646 CrossRefPubMed
61.
Zurück zum Zitat Vlachopoulos C, Aznaouridis K, Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 55(13):1318–1327 CrossRefPubMed Vlachopoulos C, Aznaouridis K, Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 55(13):1318–1327 CrossRefPubMed
62.
Zurück zum Zitat Daiber A, Steven S, Weber A et al (2017) Targeting vascular (endothelial) dysfunction. Br J Pharmacol 174(12):1591–1619 CrossRefPubMed Daiber A, Steven S, Weber A et al (2017) Targeting vascular (endothelial) dysfunction. Br J Pharmacol 174(12):1591–1619 CrossRefPubMed
63.
Zurück zum Zitat Schnabel RB, Schulz A, Wild PS et al (2011) Noninvasive vascular function measurement in the community: cross-sectional relations and comparison of methods. Circ Cardiovasc Imaging 4(4):371–380 CrossRefPubMed Schnabel RB, Schulz A, Wild PS et al (2011) Noninvasive vascular function measurement in the community: cross-sectional relations and comparison of methods. Circ Cardiovasc Imaging 4(4):371–380 CrossRefPubMed
64.
Zurück zum Zitat Muiesan ML, Salvetti M, Monteduro C et al (2004) Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 43(4):731–738 CrossRefPubMed Muiesan ML, Salvetti M, Monteduro C et al (2004) Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 43(4):731–738 CrossRefPubMed
65.
Zurück zum Zitat Galderisi M, Cosyns B, Edvardsen T et al (2017) Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 18(12):1301–1310 PubMed Galderisi M, Cosyns B, Edvardsen T et al (2017) Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 18(12):1301–1310 PubMed
66.
Zurück zum Zitat McDermott MM, Greenland P, Liu K et al (2002) The ankle brachial index is associated with leg function and physical activity: the walking and leg circulation study. Ann Intern Med 136(12):873–883 CrossRefPubMed McDermott MM, Greenland P, Liu K et al (2002) The ankle brachial index is associated with leg function and physical activity: the walking and leg circulation study. Ann Intern Med 136(12):873–883 CrossRefPubMed
67.
Zurück zum Zitat Fowkes FG, Murray GD, Butcher I et al (2008) Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300(2):197–208 CrossRefPubMed Fowkes FG, Murray GD, Butcher I et al (2008) Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300(2):197–208 CrossRefPubMed
68.
Zurück zum Zitat Haberl R, Becker A, Leber A et al (2001) Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: results of 1,764 patients. J Am Coll Cardiol 37(2):451–457 CrossRefPubMed Haberl R, Becker A, Leber A et al (2001) Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: results of 1,764 patients. J Am Coll Cardiol 37(2):451–457 CrossRefPubMed
69.
Zurück zum Zitat Tinana A, Mintz GS, Weissman NJ (2002) Volumetric intravascular ultrasound quantification of the amount of atherosclerosis and calcium in nonstenotic arterial segments. Am J Cardiol 89(6):757–760 CrossRefPubMed Tinana A, Mintz GS, Weissman NJ (2002) Volumetric intravascular ultrasound quantification of the amount of atherosclerosis and calcium in nonstenotic arterial segments. Am J Cardiol 89(6):757–760 CrossRefPubMed
70.
Zurück zum Zitat Cao JJ, Barzilay JI, Peterson D et al (2006) The association of microalbuminuria with clinical cardiovascular disease and subclinical atherosclerosis in the elderly: the cardiovascular health study. Atherosclerosis 187(2):372–377 CrossRefPubMed Cao JJ, Barzilay JI, Peterson D et al (2006) The association of microalbuminuria with clinical cardiovascular disease and subclinical atherosclerosis in the elderly: the cardiovascular health study. Atherosclerosis 187(2):372–377 CrossRefPubMed
71.
Zurück zum Zitat Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 333(20):1301–1307 CrossRefPubMed Shepherd J, Cobbe SM, Ford I et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med 333(20):1301–1307 CrossRefPubMed
72.
Zurück zum Zitat Cushman M, Arnold AM, Psaty BM et al (2005) C‑reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 112(1):25–31 CrossRefPubMed Cushman M, Arnold AM, Psaty BM et al (2005) C‑reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 112(1):25–31 CrossRefPubMed
73.
Zurück zum Zitat Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131 CrossRefPubMed Ridker PM, Everett BM, Thuren T et al (2017) Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131 CrossRefPubMed
74.
Zurück zum Zitat Albus C, Ladwig KH, Herrmann-Lingen C (2014) Psychocardiology: clinically relevant recommendations regarding selected cardiovascular diseases. Dtsch Med Wochenschr 139(12):596–601 CrossRefPubMed Albus C, Ladwig KH, Herrmann-Lingen C (2014) Psychocardiology: clinically relevant recommendations regarding selected cardiovascular diseases. Dtsch Med Wochenschr 139(12):596–601 CrossRefPubMed
76.
Zurück zum Zitat Munzel T, Sorensen M, Gori T et al (2017) Environmental stressors and cardio-metabolic disease: part I‑epidemiologic evidence supporting a role for noise and air pollution and effects of mitigation strategies. Eur Heart J 38(8):550–556 PubMed Munzel T, Sorensen M, Gori T et al (2017) Environmental stressors and cardio-metabolic disease: part I‑epidemiologic evidence supporting a role for noise and air pollution and effects of mitigation strategies. Eur Heart J 38(8):550–556 PubMed
77.
Zurück zum Zitat Peters A, von Klot S, Heier M et al (2004) Exposure to traffic and the onset of myocardial infarction. N Engl J Med 351(17):1721–1730 CrossRefPubMed Peters A, von Klot S, Heier M et al (2004) Exposure to traffic and the onset of myocardial infarction. N Engl J Med 351(17):1721–1730 CrossRefPubMed
78.
Zurück zum Zitat Thanassoulis G, Peloso GM, Pencina MJ et al (2012) A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium: the Framingham heart study. Circ Cardiovasc Genet 5(1):113–121 CrossRefPubMedPubMedCentral Thanassoulis G, Peloso GM, Pencina MJ et al (2012) A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium: the Framingham heart study. Circ Cardiovasc Genet 5(1):113–121 CrossRefPubMedPubMedCentral
79.
Zurück zum Zitat Reinhard W, Trenkwalder T, Schunkert H (2017) Practical guidelines for genetic testing in cardiovascular diseases. Herz 42(5):485–491 CrossRefPubMed Reinhard W, Trenkwalder T, Schunkert H (2017) Practical guidelines for genetic testing in cardiovascular diseases. Herz 42(5):485–491 CrossRefPubMed
80.
Zurück zum Zitat Lipshultz SE, Landy DC, Lopez-Mitnik G et al (2012) Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 30(10):1050–1057 CrossRefPubMedPubMedCentral Lipshultz SE, Landy DC, Lopez-Mitnik G et al (2012) Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy. J Clin Oncol 30(10):1050–1057 CrossRefPubMedPubMedCentral
Metadaten
Titel
Prävention von Herz-Kreislauf-Erkrankungen
verfasst von
Dr. med. J. H. Prochaska
N. Arnold
C. Jünger
T. Münzel
Univ.-Prof. Dr. med. P. S. Wild
Publikationsdatum
15.01.2018
Verlag
Springer Medizin
Erschienen in
Herz / Ausgabe 1/2018
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-017-4669-8